Merck & Co. Files 8-K: Director Changes, Compensation, Bylaws
Ticker: MRK · Form: 8-K · Filed: Nov 22, 2024 · CIK: 310158
| Field | Detail |
|---|---|
| Company | Merck & CO., INC. (MRK) |
| Form Type | 8-K |
| Filed Date | Nov 22, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-compensation, bylaws
Related Tickers: MRK
TL;DR
Merck's 8-K: New directors elected, exec pay tweaked, bylaws amended. Governance update.
AI Summary
On November 19, 2024, Merck & Co., Inc. filed an 8-K report detailing several key events. The company announced the election of new directors and changes in officer compensation arrangements. Additionally, Merck & Co., Inc. filed amendments to its articles of incorporation and bylaws, and provided financial statement exhibits.
Why It Matters
This filing indicates potential shifts in corporate governance and executive compensation, which could impact the company's strategic direction and investor relations.
Risk Assessment
Risk Level: low — The filing primarily concerns routine corporate governance updates and financial disclosures, with no immediate negative financial implications apparent.
Key Players & Entities
- Merck & Co., Inc. (company) — Filer of the 8-K report
- 2024-11-19 (date) — Date of report and key events
- 20241122 (date) — Filing date of the 8-K
FAQ
Who were the newly elected directors?
The filing indicates the election of new directors but does not name them in the provided text.
What specific changes were made to officer compensation arrangements?
The filing states that there were changes to compensatory arrangements of certain officers, but the specific details are not provided in this excerpt.
What were the key amendments to the articles of incorporation or bylaws?
The filing notes amendments to the articles of incorporation or bylaws, but the specific content of these amendments is not detailed in the provided text.
What financial statements and exhibits were filed?
The filing indicates that financial statements and exhibits were filed, but their specific content is not described in this excerpt.
What is Merck & Co., Inc.'s fiscal year end?
Merck & Co., Inc.'s fiscal year ends on December 31st.
Filing Stats: 779 words · 3 min read · ~3 pages · Grade level 9 · Accepted 2024-11-22 14:28:06
Key Financial Figures
- $0.50 — nge on which registered Common Stock ($0.50 par value) MRK New York Stock Exchang
Filing Documents
- tm2429161d1_8k.htm (8-K) — 40KB
- tm2429161d1_ex3-1.htm (EX-3.1) — 109KB
- tm2429161d1_ex99-1.htm (EX-99.1) — 10KB
- tm2429161d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-24-122027.txt ( ) — 443KB
- mrk-20241119.xsd (EX-101.SCH) — 5KB
- mrk-20241119_def.xml (EX-101.DEF) — 28KB
- mrk-20241119_lab.xml (EX-101.LAB) — 39KB
- mrk-20241119_pre.xml (EX-101.PRE) — 27KB
- tm2429161d1_8k_htm.xml (XML) — 11KB
02. Departure of Directors or Certain Officers; Election
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Incorporated by reference is a press release issued by Merck & Co., Inc. (the "Company") on November 22, 2024, attached as Exhibit 99.1, announcing the election of Surendralal L. "Lal" Karsanbhai to the Company's Board of Directors (the "Board"), effective January 1, 2025. The Board appointed Mr. Karsanbhai as a member of both the Audit and Governance Committees of the Board. For his service on the Board, Mr. Karsanbhai will receive compensation as a non-employee director in accordance with the Company's non-employee director compensation practices described under the "Director Compensation" section of the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 11, 2024. Mr. Karsanbhai has no arrangements or understandings with any other person pursuant to which he was elected to the Board, nor does he have a relationship or related transaction with the Company that would require disclosure pursuant to Item 404(a) of Regulation S-K of the Securities and Exchange Commission in connection with his appointment as a director of the Company.
03. Amendments to Articles of Incorporation or Bylaws;
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year . On November 19, 2024, the Board approved and adopted amended and restated by-laws of the Company (as so amended and restated, the "By-Laws"), effective as of such date. The amendments to the By-Laws revise and update the indemnification provisions applicable to the Company's directors, officers, employees and agents. In addition, certain other non-substantive and conforming revisions were made to the By-Laws. The foregoing description of the By-Laws does not purport to be complete and is qualified in its entirety by reference to the full text of the By-Laws, a copy of which is attached as Exhibit 3.1 hereto and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits . (d) Exhibits Exhibit 3.1 By-Laws of Merck & Co., Inc., as amended and restated on November 19, 2024. Exhibit 99.1 Press release issued November 22, 2024. Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Merck & Co., Inc. Date: November 22, 2024 By: /s/ Kelly E. W. Grez Kelly E. W. Grez Corporate Secretary